The purpose of this study is to measure clinical safety and efficacy of oral brepocitinib in adult participants with cutaneous sarcoidosis.
Study details include:

• Up to 30 days for screening (Screening Period), then
• 16 weeks of treatment with double-blinded treatment with either brepocitinib 45 mg, brepocitinib 15 mg, or placebo (Treatment Period) QD, then
• 4 weeks for safety follow-up (Off-Drug Follow-Up Period)
• The visit frequency is every 4 weeks.
• Ongoing standard of care (that meets eligibility criteria requirements) will be maintained during the Treatment Period. Participants who are receiving ongoing oral corticosteroids at baseline will undergo a mandatory taper (starting with Day 15, Week 2) and discontinue oral corticosteroids on or before Day 57 (Week 8).

• Current sarcoidosis disease presentation consistent with any of the following: 
  • Solely subcutaneous sarcoidosis;
  • Solely nongranulomatous or nonspecific cutaneous sarcoidosis lesions (e.g., erythema nodosum);
  • Solely ulcerative lesions;
  • Lofgren’s syndrome
• History of any lymphoproliferative disorder (such as Epstein-Barr virus [EBV]-related lymphoproliferative disorder, lymphoma, leukemia).
• Cancer-associated condition, cancer, or history meeting any of the following conditions:
  • Active malignancy;
  • History of cancer within 5 years prior to baseline
• Severe hepatic impairment
• Any of the following cardiovascular risk factors including the following:
  • Cardiac insufficiency
  • Myocardial infarction (MI) within 1 year prior to baseline
  • Coronary artery bypass graft surgery within 1 year prior to baseline
• Recipient of a solid organ transplant who is currently receiving systemic immunosuppressive therapy.
• Any condition possibly affecting oral drug absorption (e.g., gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass).
• Current therapy consisting of > 25 mg/day of prednisone or equivalent or a change in corticosteroid dose in the 4 weeks prior to baseline
• Current or planned treatment with prohibited concomitant medications, including biologic therapy (e.g., TNF inhibitors)